Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.

ABSTRACT:

Background

Talazoparib monotherapy in patients with germline BRCA-mutated, early-stage triple-negative breast cancer (TNBC) showed activity in the neoadjuvant setting in the phase II NEOTALA study (NCT03499353). These biomarker analyses further assessed the mutational landscape of the patients enrolled in the NEOTALA study.

Methods

Baseline tumor tissue from the NEOTALA study was tested retrospectively using FoundationOne^®CDx. To further hypothesis-driven correlative analyses, agnostic heat-map visualizations of the FoundationOne^®CDx tumor dataset were used to assess overall mutational landscape and identify additional candidate predictive biomarkers of response.

Results

All patients enrolled (N = 61) had TNBC. In the biomarker analysis populatio

SUBMITTER: Telli ML 

PROVIDER: S-EPMC11341741 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature